Top Midday Stories: DigitalBridge to Be Acquired by SoftBank; Ultragenyx's Brittle Bone Disease Drug Studies Miss Primary Endpoints

MT Newswires Live
2025/12/30

All three major US stock indexes were down in late-morning trading Monday to kick off the final few trading days of the year.

In company news, DigitalBridge (Group DBRG) has agreed to be acquired by SoftBank Group for about $4 billion, SoftBank said Monday. Under the terms of the deal, SoftBank will indirectly acquire all outstanding shares of DigitalBridge for $16 each in cash, representing a 15% premium over DigitalBridge's closing share price on Dec. 26. The deal is expected to close in H2 of 2026, the company said. DigitalBridge shares were up 9.6% around midday.

Ultragenyx Pharmaceutical (RARE) and its collaboration partner Mereo BioPharma (MREO) said Monday that phase 3 studies of setrusumab to treat Osteogenesis Imperfecta did not achieve the primary endpoints of reduction in annualized clinical fracture rate compared to a placebo or bisphosphonates. Ultragenyx shares were down 44.3%, while Mereo shares were off 90.5%.

Lululemon Athletica's (LULU) founder and major shareholder Chip Wilson said Monday he is nominating three independent director candidates for the company's board, to be voted on at the 2026 annual shareholders' meeting. Lululemon shares were up 0.7%.

Coupang (CPNG) said Monday it will start a 1.685 trillion won ($1.18 billion) compensation program following a recent personal data breach. Coupang shares were up 1.2%.

Energy Fuels (UUUU) said Monday it exceeded its previous guidance for finished uranium production, mined uranium ore production and uranium concentrate sales for 2025. Energy Fuels shares were up 6.3%.

Price: 15.27, Change: +1.35, Percent Change: +9.70

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10